These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19591405)

  • 41. Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial.
    Delaloye AB; Antonescu C; Louton T; Kuhlmann J; Hagenbeek A
    J Nucl Med; 2009 Nov; 50(11):1837-43. PubMed ID: 19837764
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
    Wiseman GA; Conti PS; Vo K; Schilder RJ; Gordon LI; Emmanouilides C; Silverman DH; Witzig TE; Darif M; Molina A
    Clin Lymphoma Myeloma; 2007 Sep; 7(8):514-7. PubMed ID: 18021468
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan.
    Fisher DR; Shen S; Meredith RF
    J Nucl Med; 2009 Apr; 50(4):644-52. PubMed ID: 19289440
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan.
    Arrichiello C; Aloj L; Mormile M; D'Ambrosio L; Frigeri F; Caracò C; Arcamone M; De Martinis F; Pinto A; Lastoria S
    Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):956-66. PubMed ID: 22237846
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.
    Ibatici A; Pica GM; Nati S; Vitolo U; Botto B; Ciochetto C; Petrini M; Galimberti S; Ciabatti E; Orciuolo E; Zinzani PL; Cascavilla N; Guolo F; Fraternali Orcioni G; Carella AM
    Br J Haematol; 2014 Mar; 164(5):710-6. PubMed ID: 24344981
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
    Shen S; Forero A; Meredith RF; Shah JJ; Knox SJ; Wiseman GA; Usrey ME; Lobuglio AF
    J Nucl Med; 2010 Jan; 51(1):150-7. PubMed ID: 20008989
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
    Hainsworth JD; Spigel DR; Markus TM; Shipley D; Thompson D; Rotman R; Dannaher C; Greco FA
    Clin Lymphoma Myeloma; 2009 Jun; 9(3):223-8. PubMed ID: 19525191
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma.
    Vaklavas C; Meredith RF; Shen S; Knox SJ; Micallef IN; Shah JJ; LoBuglio AF; Forero-Torres A
    Cancer Biother Radiopharm; 2013 Jun; 28(5):370-9. PubMed ID: 23530878
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma.
    Iwamoto FM; Schwartz J; Pandit-Taskar N; Peak S; Divgi CR; Zelenetz AD; Humm J; Abrey LE
    Cancer; 2007 Dec; 110(11):2528-34. PubMed ID: 17932895
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas.
    Ferrucci PF; Vanazzi A; Grana CM; Cremonesi M; Bartolomei M; Chinol M; Ferrari M; Radice D; Papi S; Martinelli G; Paganelli G
    Br J Haematol; 2007 Nov; 139(4):590-9. PubMed ID: 17979944
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Longer intervals between hematopoietic stem cell transplantation and subsequent 90Y-ibritumomab radioimmunotherapy may correlate with better tolerance.
    Buchegger F; Prior JO; Allenbach G; Baechler S; Kosinski M; Helg C; Chalandon Y; Ratib O; Delaloye AB; Ketterer N
    Clin Nucl Med; 2012 Oct; 37(10):960-4. PubMed ID: 22955069
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 90Y-ibritumomab therapy in refractory non-Hodgkin's lymphoma: observations from 111In-ibritumomab pretreatment imaging.
    Iagaru A; Gambhir SS; Goris ML
    J Nucl Med; 2008 Nov; 49(11):1809-12. PubMed ID: 18927323
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
    J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
    Karmali R; Kassar M; Venugopal P; Shammo JM; Fung HC; Bayer R; O'Brien T; Gregory SA
    Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):467-74. PubMed ID: 21700527
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
    Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS
    J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan. Clinical considerations, radiopharmacy, radiation protection, perspectives].
    Schomäcker K; Dietlein M; Schnell R; Pinkert J; Eschner W; Zimmermanns B; Fischer T; Engert A; Schicha H
    Nuklearmedizin; 2005; 44(4):166-77. PubMed ID: 16163413
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop.
    Zinzani PL; d'Amore F; Bombardieri E; Brammer C; Codina JG; Illidge T; Jurczak W; Linkesch W; Morschhauser F; Vandenberghe E; Van Hoof A
    Eur J Cancer; 2008 Feb; 44(3):366-73. PubMed ID: 18194857
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.
    Zinzani PL; Tani M; Fanti S; Stefoni V; Musuraca G; Vitolo U; Perrotti A; Fina M; Derenzini E; Baccarani M
    Cancer; 2008 Feb; 112(4):856-62. PubMed ID: 18189293
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ibritumomab tiuxetan for non-Hodgkin's lymphoma.
    Johnston PB; Bondly C; Micallef IN
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):861-9. PubMed ID: 16761929
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma.
    Lindén O; Kurkus J; Garkavij M; Cavallin-Ståhl E; Ljungberg M; Nilsson R; Ohlsson T; Sandberg B; Strand SE; Tennvall J
    Cancer Biother Radiopharm; 2005 Aug; 20(4):457-66. PubMed ID: 16114994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.